Good news! Norovirus tetravalent vaccine developed in China has officially entered clinical research.

　　Shanghai, June 4th (Reporter Jiang Hongbing) The tetravalent recombinant norovirus vaccine developed by Shanghai Pasteur Institute of China Academy of Sciences has been approved by National Medical Products Administration recently, and has officially entered clinical research as a national class I preventive biological product.

　　Norovirus is the number one pathogen of acute viral gastroenteritis. How to develop a vaccine with broad protection has been an international problem for decades. Huang Zhong, a researcher from Shanghai Pasteur Institute, led the research team to construct a multivalent recombinant Norovirus vaccine prototype based on virus-like particles (VLP) by using genetic engineering technology. In April 2015, the Institute signed a cooperation agreement with Zhifei Bio to jointly develop a multivalent norovirus vaccine. The two sides worked together to tackle key problems, and it took four years to complete the pre-clinical research and development and clinical trial application of tetravalent recombinant norovirus vaccine (Pichia pastoris), and now it has been approved to carry out clinical trials. The vaccine contains recombinant virus-like particle antigens of four major Norovirus epidemic genotypes, which can theoretically prevent 80%— 90% norovirus infection and acute gastroenteritis caused by norovirus are the multivalent norovirus vaccine with the second highest clinical license price in the world.